Invisible symptoms of multiple sclerosis (MS), including fatigue, cognitive/mood impairment, and sensory disturbances, are major contributors to functional decline and diminished quality of life (QoL), yet remain understudied, underrecognized, and undertreated in people with MS. In this session, we will identify and characterize these invisible symptoms, explore their relationship to clinical outcomes and QoL, and apply evidence-based strategies for their effective management. The session opens with a brief introduction and overview of common invisible symptoms in MS and their disproportionate impact on QoL despite minimal objective physical findings. Dr. Singh explores fatigue and sleep disturbances in people with MS, reviewing the mechanisms underlying these symptoms, outlining a diagnostic approach to evaluate and differentiate contributing factors, and presenting evidence-based management strategies including both pharmacologic and behavioral interventions. Dr. Shin will review challenging subclinical visual symptoms and the role of the clinical examination and optical coherence tomography (OCT) in MS. Dr. Simpson will discuss translating invisible symptom assessment into research and practice, highlighting the role of patient-reported outcome measures, real-world data, and novel analytical approaches in capturing heterogeneity of symptom burden among people living with MS. A brief Q&A and panel discussion will conclude the session, focusing on practical strategies to recognize and address invisible symptoms in routine multidisciplinary MS care. All presentations will be delivered by MS neurologists with complementary clinical and research expertise in fatigue, neuro-ophthalmology, and/or invisible symptom burden. Level of Information: Basic, IntermediateInvisible symptoms of multiple sclerosis (MS), including fatigue, cognitive/mood impairment, and sensory disturbances, are major contributors to functional decline and diminished quality of life (QoL), yet remain understudied, underrecognized, and undertreated in people with MS. In this session, we will identify and characterize these invisible symptoms, explore their relationship to clinical outcomes and QoL, and apply evidence-based strategies for their effective management. The session opens with a brief introduction and overview of common invisible symptoms in MS and their disproportionate impact on QoL despite minimal objective physical findings. Dr. Singh explores fatigue and sleep disturbances in people with MS, reviewing the mechanisms underlying these symptoms, outlining a diagnostic approach to evaluate and differentiate contributing factors, and presenting evidence-based management strategies including both pharmacologic and behavioral interventions. Dr. Shin will review challenging subclinical visual symptoms and the role of the clinical examination and optical coherence tomography (OCT) in MS. Dr. Simpson will discuss translating invisible symptom assessment into research and practice, highlighting the role of patient-reported outcome measures, real-world data, and novel analytical approaches in capturing heterogeneity of symptom burden among people living with MS. A brief Q&A and panel discussion will conclude the session, focusing on practical strategies to recognize and address invisible symptoms in routine multidisciplinary MS care. All presentations will be delivered by MS neurologists with complementary clinical and research expertise in fatigue, neuro-ophthalmology, and/or invisible symptom burden. Level of Information: Basic, Intermediate